STING1 and neoplasm: Similarly, combination treatment with ADU-S100 and 5AZADC significantly delayed tumor growth in the aggressive model of B16-ISG (p < 0.0001 on day 21) (Fig. 4d); however, it failed to induce tumor control in the STING-deficient B16-ISG-STINGKO model (Fig. 4e) suggesting a critical role for STING in mediating antitumor responses to the combination therapy.